This site is intended for healthcare professionals only

COVID-19: Antibody therapy approved for UK use

Written by: | Published:

The new treatment has been approved for use The new treatment has been approved for use

A new coronavirus treatment has been approved for use in the UK.

The therapy uses a pair of laboratory-made antibodies to attack the virus. Regulators have said the drug Ronapreve had been shown to prevent infection and reduce the need for hospital treatment. However, it is very expensive and likely to be reserved for those at greatest risk of becoming severely ill.

Read more: Self-isolation to be eased for fully vaccinated adults

‘This is very good news – this is the second ‘antiviral’ therapeutic to be licensed for COVID in the UK (the first was remdesivir) and the product has been shown to both reduce the need for hospitalisation and death when started early (within 3 days of a positive PCR test) among subjects infected with SARS CoV2 and to prevent illness in close contacts of infected individuals,’ said Proffessor Penny Ward, Independent Pharmaceutical Physician, Visiting Professor in Pharmaceutical Medicine at Kings College, London.

‘Although not included in the data submitted to support this approval, the antibody has also been used in the RECOVERY trial, where it reduced length of hospitalisation and reduced mortality in seronegative patients with COVID admitted to hospital.’

The drug costs between £1,000 to £2,000 for one course of treatment. All monoclonal antibodies, unlike the chemical drugs purchased in pharmacies, are challenging and expensive to make.

Read more: Vital for pinged people to self-isolate

‘The challenge going forward will be in determining which patients should be prioritised for this treatment. COVID is not a rare disease and many people get better of their own accord after a few days of a nasty flu-like illness,’ said Proffessor Martin Landray, Professor of Medicine & Epidemiology, Nuffield Department of Population Health, University of Oxford.

‘ It would be hard to justify giving what are likely to be limited supplies of a relatively expensive treatment to huge numbers of people who are likely to get better on their own. On the other hand, it may play an important role in patients who are at higher risk of developing severe infection and who are more likely to end up in hospital.’

What do you think? Leave a comment below or tweet your views to @IndyNurseMag

This material is protected by MA Healthcare Ltd copyright.
See Terms and Conditions.



Please view our Terms and Conditions before leaving a comment.

Change the CAPTCHA codeSpeak the CAPTCHA code

Read a free issue from Practice Nursing

Register to read a free issue from our sister publication, Practice Nursing.

Including articles on asthma, diabetes and more. Read your copy.


Sign up to the newsletter


Independent Nurse is the professional resource for primary care and community nurses, providing clinical articles for practice nurses and prescribers.


Subscribe to our newsletter and stay up to date with the latest nursing news.

Stay Connected

Stay social with Independent Nurse by following us on Twitter, liking us on Facebook or connecting on LinkedIn.


Need access to some of our older articles? You can view our archive, or alternatively contact us.

Contact Us

MA Healthcare Ltd.
St Jude's Church, Dulwich Road
London, SE24 0PB

Tel: +44 (0)20 7738 5454
Registered in England and Wales No. 01878373

Meet the team


Find out how to contribute to Independent Nurse here.